Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies

Greer, Ian A.; Lowe, G. D. O.; Walker, James J.; Forbes, C. D.

doi:10.1111/j.1471-0528.1991.tb13514.x

Cited by 176 publications

(138 citation statements)

References 26 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…A report from Sweden showed that 9/136 women with VWD (6.8%) experienced hemorrhagic ovarian cysts [27]. There have also been reports of bleeding into the broad ligament with the patient presenting with a positive iliopsoas sign [28].…”

Section: Clinical Characteristicsmentioning

confidence: 99%

“…This meets or exceeds the criteria for primary PPH [1]. Also, there appears to be a higher rate in type 2 (three patients) compared to type 1 patients [1, 23,28]. This may result in the need for red cell transfusions in between 7% [1] and 17% [5] of type 1 patients.…”

Section: Obstetric Aspectsmentioning

confidence: 99%

“…Five of the 4067 women with VWD died, a maternal mortality rate 10 times higher than that for other women [44]. Besides an increased rate of PPH in VWD women, perineal hematomas appear to be more common [1,28].…”

Section: Obstetric Aspectsmentioning

confidence: 99%

See 2 more Smart Citations

Women and Von Willebrand Disease

Kouides¹

2014

Textbook of Hemophilia

View full text Add to dashboard Cite

Section: Clinical Characteristicsmentioning

confidence: 99%

Section: Obstetric Aspectsmentioning

confidence: 99%

See 1 more Smart Citation

Women and Von Willebrand Disease

Kouides¹

2014

Textbook of Hemophilia

View full text Add to dashboard Cite

“…Platelets contain 10%–15% of total blood vWF, and platelet transfusions have been used successfully to treat bleeding in patients with vWD 48. Platelet transfusion should be considered in patients with type 3 or platelet-low vWD to control bleeding that is not responsive or poorly responsive to replacement therapy with vWF concentrate.…”

Section: Adjunctive Treatmentsmentioning

confidence: 99%

Treatment of patients with von Willebrand disease

Tuohy

Litt²,

Alikhan³

2011

JBM

View full text Add to dashboard Cite

Von Willebrand disease (vWD) is the most common hereditary bleeding disorder. The aim of therapy is to correct the dual hemostatic defect, due to defective platelet adhesion-aggregation and abnormal coagulation due to Factor VIII (FVIII) deficiency. The choice of treatment depends on a number of factors, including the severity of the bleed, the procedure planned, the subtype and severity of the disease and the age and morbidity of the patient. Desmopressin (DDAVP) is the treatment of choice for type 1 vWD as it increases endogenous release of FVIII and von Willebrand factor (vWF) and is also used in some subtypes of type 2 vWD. In those patients in whom DDAVP is ineffective or contraindicated, levels can be restored by infusing vWF:FVIII concentrates. The role of antifibrinolytic treatment is an important adjunct to replacement therapy during minor or major surgery involving mucosal surfaces. The dosing and timing of vWF:FVIII concentrates is important depending on the nature of the surgical procedure. The role of secondary prophylaxis needs to be further defined.

show abstract

“…Zu einem ähnlichen Ergebnis kamen Greer et al [13] in ihrer Studie. Der Erfolg der Therapie mit oralen Kontrazeptiva kann durch einen Anstieg der F VIII C-und vWF-Spiegel gezeigt werden [6].…”

Section: Von Willebrand-jürgens-syndromunclassified

Contraception in Chronically ill Adolescents

Drexel-Fink¹,

Peters²

2002

Zentralbl Gynakol

View full text Add to dashboard Cite

Contraception in chronically ill adolescents has to consider side effects with regard to metabolic or hematological disease. Additionally the compliance of the patient has to be taken in account when consulting about contraceptives. In juvenile diabetics with good glycemic control and metabolic diseases of the amino acids oral contraceptives are justifiable. Adolescents with galactose-mia mostly suffer from premature ovarian failure and therefore have to be controlled wether they need contraception at all. Young women with sickle-cell anemia are at risk of thrombophilia. They should not be given hormonal contraceptives. In v. Willebrand-Jürgens-Syndrome oral contraceptives are favourable because it alleviates menorrhagia.

show abstract

Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies

Abstract: Objective-To review the obstetric and gynaecological problems in women with congenital coagulopathics. Design-Retrospective rcview.

Cited by 176 publications

References 26 publications

Women and Von Willebrand Disease

Women and Von Willebrand Disease

Treatment of patients with von Willebrand disease

Contraception in Chronically ill Adolescents

Contact Info

Product

Resources

About